Events
63rd ERA congress, the Annual Nephrology Congress in Europe
ENYO Pharma will participate in the 63rd ERA congress scheduled for June 3-6, 2026, in Glasgow, UK. The event will highlight advancements and discussions in nephrology, contributing to the ongoing dialogue in the field. More information is available at the ERA website.
The 26th Bio€quity Europe 2026, Prague
May 4-6, 2026
Prague, Czech Republic
ENYO Pharma is attending Bio€quity Europe on May 4-6, 2026 in Prague, engaging with venture investors to discuss near and mid term value creation across our kidney disease pipeline to accelerate the clinical advancement of Vonafexor and EYP651 in various kidney diseases.
The main focus during the event will be on the positive Phase 2 ALPESTRIA 1 results in Alport syndrome.
https://conferences.biocentury.com/bioequity-europe-2026/schedule
J.P. Morgan week in San Francisco, 2026
11-15 January, 2026
San Francisco, CA, USA
ENYO Pharma will be in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
ASN – the American Society of Nephrology 2025
5-9 November 2025
Houston, Texas
ENYO Pharma will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN.
The 2025 International Workshop on Alport Syndrome
5-7 September 2025
Beijing, China
ENYO Pharma will attend The 2025 International Workshop on Alport Syndrome, organized by Alport Syndrome Alliance.
It is an opportunity for the Alport community to connect, update and discuss the latest research.
ENYO Pharma will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.
Latest Press Release 